What is the usual dose of mirtazapine for depression vs insomnia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine Dosing for Depression vs Insomnia

For depression, mirtazapine should be dosed at 15-45 mg daily, while for insomnia alone, a lower dose of 7.5-15 mg at bedtime is typically effective.

Dosing for Depression

Initial Dosing

  • Start with 15 mg once daily, administered orally in the evening prior to sleep 1
  • Allow 1-2 weeks between dose adjustments to properly evaluate response 1
  • Titrate upward if needed, using increments of the initial dose

Maintenance Dosing

  • Effective dosage range: 15-45 mg daily 2, 1
  • Maximum recommended dose: 30 mg at bedtime according to guidelines 2
  • A full therapeutic trial requires 4-8 weeks to determine efficacy 2

Therapeutic Considerations

  • Mirtazapine is potent and well-tolerated for depression 2
  • The onset of clinical effect typically occurs in 2-4 weeks, though sleep disturbances and anxiety symptoms may improve within the first week 3
  • Higher doses (30-45 mg) tend to be less sedating than lower doses due to increased noradrenergic effects at higher doses

Dosing for Insomnia

Initial Dosing

  • For insomnia without depression: 7.5 mg at bedtime 2
  • Lower doses (7.5-15 mg) are more sedating than higher doses due to predominant H1 receptor antagonism

Therapeutic Considerations

  • Mirtazapine is effective for insomnia in patients with autism spectrum disorders at doses starting at 7.5 mg 2
  • It promotes sleep, appetite, and weight gain even at lower doses 2
  • Particularly effective for sleep maintenance insomnia and may help with early morning awakenings 4

Dosing Algorithm

  1. For primary depression with sleep disturbance:

    • Start with 15 mg at bedtime
    • Assess response after 1-2 weeks
    • If inadequate response, increase by 15 mg increments up to 45 mg daily
    • Maximum dose: 45 mg daily
  2. For primary insomnia without significant depression:

    • Start with 7.5 mg at bedtime
    • Maintain at lower dose (7.5-15 mg) if effective for sleep
    • Do not exceed 15 mg if treating insomnia alone

Important Clinical Considerations

  • Pharmacological mechanism: At lower doses (≤15 mg), mirtazapine primarily blocks histamine H1 receptors, producing sedation. At higher doses, increased noradrenergic and serotonergic effects become more prominent, potentially reducing sedation 5

  • Common side effects:

    • Somnolence (especially at lower doses)
    • Increased appetite and weight gain
    • Dizziness 6, 5
  • Monitoring:

    • Follow up within 7-10 days of initiating treatment to assess sleep quality and side effects 4
    • Monitor for increased appetite and weight gain, which may worsen sleep apnea 4
  • Discontinuation:

    • Gradually reduce the dosage rather than stopping abruptly to prevent withdrawal symptoms 1
    • Taper over 10-14 days when discontinuing 2
  • Drug interactions:

    • Avoid concurrent use with MAOIs (allow 14 days between stopping one and starting the other) 1
    • Dose adjustments may be needed with strong CYP3A inducers or inhibitors 1

Mirtazapine offers the advantage of improving sleep without the tolerance or dependence issues associated with benzodiazepines, making it a valuable option for patients with both depression and insomnia 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Sleep Management Guideline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Research

Mirtazapine, an antidepressant.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.